Novo Nordisk
2012-10-25T16:53:04Z
2012-10-25T16:53:04Z
FDA discloses focus of Advisory Committee meeting on insulin degludec and insulin degludec/insulin aspart
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has published information pertaining to the focus of the Advisory Committee meeting scheduled for 8 November 2012 to discuss the New Drug Applications for insulin degludec and insulin degludec/insulin aspart.
Further information:
Media: | Investors: |
| Mike Rulis | Kasper Roseeuw Poulsen |
| Tel: (+45) 3079 3573 | Tel: (+45) 4442 4303 |
| mike@novonordisk.com | krop@novonordisk.com |
| Frank Daniel Mersebach | |
| Tel: (+45) 4442 0604 | |
| fdni@novonordisk.com | |
| Lars Borup Jacobsen | |
| Tel: (+45) 3075 3479 | |
| lbpj@novonordisk.com | |
| In North America: | |
| Ambre Morley | Jannick Lindegaard |
| Tel: (+1) 609 216 5240 | Tel: (+1) 609 786 4575 |
| abmo@novonordisk.com | jlis@novonordisk.com |
Company announcement No 68 / 2012